DELVE INTO AFRICAN WEALTH
DON'T MISS A BEAT
Subscribe now
Skip to content

South African billionaire Stephen Saad suffers over $100-million loss in just 72 days

Saad, who founded Aspen in 1997, owns a 12.5-percent stake, or 57,151,972 ordinary shares, in the branded pharmaceutical holding company.

Stephen Saad
Stephen Saad

Table of Contents

South African billionaire and pharmaceutical tycoon, Stephen Saad’s stake in Durban-based pharmaceutical company Aspen Pharmacare Holdings has dropped by more than $100 million recently as investors booked profits in the pharmaceutical company.

According to data tracked by Billionaires.Africa, Saad, a leading pharma tycoon who ranks as one of Africa’s billionaires, has seen the market value of his stake in Aspen slump by R2.08 billion ($108.39 million) in the past 72 days.

Aspen, a global specialty and branded pharmaceutical industry leader, has a strong presence in the pharmaceutical sector spanning over two decades, improving patients’ health in over 115 countries.

Saad, who founded the leading group in 1997, owns a 12.5-percent stake, which amounts to 57,151,972 ordinary shares in the branded pharmaceutical holding company. The stake, which is presently worth more than $480 million, makes him one of Africa’s richest people.

Since Aug. 10, exactly 72 days ago, Aspen shares on the Johannesburg Stock Exchange have decreased by 18.21 percent, falling from R199.44 ($10.435) on August 10 to R163.12 ($8.533) at the time of writing, thus leading to losses amounting to millions of dollars for its shareholders, including the affluent Saad.

As a result of the double-digit percent slump in the group’s share price, the market value of the stake held by Saad has slumped by R2.08 billion ($108.39 million) in just 72 days, from R11.40 billion ($595.20 million) on Aug. 10 to R9.32 billion ($486.81 million) at the time of writing.

Despite the recent decline in the company’s shares, Saad maintains his position as one of the affluent billionaires in South Africa but also one of the renowned investors on the Johannesburg Stock Exchange.

The intelligence satisfies curiosity. The paid briefings satisfy strategy.

Every Monday, Elite subscribers receive an Investor Memo breaking down the deal, the structure and the positioning behind the week's most consequential African wealth story - the kind of analysis that doesn't appear anywhere else.

Twice a month, a Wealth Intelligence brief profiles a single billionaire's holdings, cash flows and expansion pipeline in detail no public source matches.

Executive ($25/mo): Daily newsletter + Deep-Dive Reports

Elite ($75/mo): Everything above + Investor Memos + Wealth Intelligence + Quarterly Analyst Briefings

Subscribe now

Latest